EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

Ecaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh iD, Melissa L Johnson, Anthony W Tolcher, John A Thompson, Anthony B El-Khoueiry, Andrae L Vandross, Shivaani Kummar, Dale R Shepard, Kim LeDuke, Lisa Sheehan und 5 weitere

New England Journal of Medicine · 26.02.2026 · 394 (9) · 872-883

DOI: 10.1056/nejmoa2508820 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 26.02.2026. Verfasst von Ecaterina E Dumbrava und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas M.D. Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Tumor Suppressor Protein p53, Drugs, Investigational. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: This study was sponsored by PMV Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsTumor Suppressor Protein p53Drugs, InvestigationalAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugMaximum Tolerated DoseMutationProtein StabilityAdministration, OralNauseaVomitingAnemiaCreatinineFatigueProof of Concept StudyTreatment Outcome

Substanzen

Antineoplastic AgentsTumor Suppressor Protein p53Drugs, InvestigationalCreatinine

Autor:innen und Institutionen

  • University of Texas M.D. Anderson Cancer Center, Houston.
  • Dana-Farber Cancer Institute, Boston.
  • Massachusetts General Hospital, Boston.
  • Sarah Cannon Research Institute, Nashville.
  • NEXT Oncology, Austin, Texas.
  • Fred Hutchinson Cancer Center, Seattle.

ORCID-Profile: Aparna R Parikh

Förderung

  • This study was sponsored by PMV Pharmaceuticals, Inc.

Zitieren

APA

Dumbrava, E. E., Shapiro, G. I., Parikh, A. R., Johnson, M. L., Tolcher, A. W., Thompson, J. A., El-Khoueiry, A. B., Vandross, A. L., Kummar, S., Shepard, D. R., LeDuke, K., Sheehan, L., Alland, L., Haque, A., Jalota, D., Fellous, M., & Schram, A. M. (2026). Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors. New England Journal of Medicine, 394(9), 872-883. https://doi.org/10.1056/nejmoa2508820

Vancouver

Dumbrava EE, Shapiro GI, Parikh AR, Johnson ML, Tolcher AW, Thompson JA, et al. Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors. New England Journal of Medicine. 2026;394(9):872-883. doi:10.1056/nejmoa2508820

BibTeX
@article{Dumbrava2026,
  author = {Dumbrava, Ecaterina E and Shapiro, Geoffrey I and Parikh, Aparna R and Johnson, Melissa L and Tolcher, Anthony W and Thompson, John A and El-Khoueiry, Anthony B and Vandross, Andrae L and Kummar, Shivaani and Shepard, Dale R and LeDuke, Kim and Sheehan, Lisa and Alland, Leila and Haque, Arshad and Jalota, Deepika and Fellous, Marc and Schram, Alison M},
  title = {Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {9},
  pages = {872--883},
  doi = {10.1056/nejmoa2508820}
}
Kostenlos starten →